Wells Fargo Maintains Equal-Weight on Arcus Biosciences, Raises Price Target to $26
Arcus Biosciences, Inc.
Arcus Biosciences, Inc. RCUS | 0.00 |
Wells Fargo analyst Eva Fortea Verdejo maintains Arcus Biosciences (NYSE:
RCUS) with a Equal-Weight and raises the price target from $23 to $26.